First Hawaiian Bank reduced its holdings in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 39.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,788 shares of the company's stock after selling 6,892 shares during the period. First Hawaiian Bank's holdings in Phibro Animal Health were worth $230,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in PAHC. Acadian Asset Management LLC boosted its stake in shares of Phibro Animal Health by 0.5% during the 1st quarter. Acadian Asset Management LLC now owns 782,939 shares of the company's stock worth $16,713,000 after buying an additional 4,144 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company's stock worth $724,000 after purchasing an additional 13,404 shares during the last quarter. Millennium Management LLC increased its stake in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company's stock worth $7,733,000 after purchasing an additional 154,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock worth $260,000 after purchasing an additional 546 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of Phibro Animal Health during the 1st quarter worth about $385,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.
Phibro Animal Health Stock Down 1.7%
NASDAQ PAHC traded down $0.68 during trading hours on Friday, hitting $39.86. 554,817 shares of the company traded hands, compared to its average volume of 392,423. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $41.57. The business's 50-day moving average is $32.87 and its 200-day moving average is $26.07. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of 33.78, a P/E/G ratio of 1.20 and a beta of 0.89.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The firm had revenue of $378.70 million during the quarter, compared to analyst estimates of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Sell-side analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.
Phibro Animal Health Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd will be given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 3rd. Phibro Animal Health's dividend payout ratio (DPR) is 40.68%.
Insider Activity
In related news, CEO Jack Bendheim sold 3,520 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $41.29, for a total value of $145,340.80. Following the sale, the chief executive officer owned 41,880 shares in the company, valued at approximately $1,729,225.20. This trade represents a 7.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 50.07% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on PAHC shares. BNP Paribas raised shares of Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. Morgan Stanley set a $34.00 price objective on shares of Phibro Animal Health in a research note on Thursday, August 28th. BNP Paribas Exane upgraded shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price objective for the company in a report on Monday, June 16th. Zacks Research cut shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 28th. Finally, Bank of America raised their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the stock an "underperform" rating in a research note on Friday, August 29th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $28.40.
Get Our Latest Analysis on Phibro Animal Health
About Phibro Animal Health
(
Free Report)
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Read More

Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.